User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy.

  • Open access
  • PDF
  • 1.09 M
Bibliographic reference Barratt, Jonathan ; Lafayette, Richard ; Kristensen, Jens ; Stone, Andrew ; Cattran, Daniel ; et. al. Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy.. In: Kidney international, Vol. 103, no. 2, p. 391-402 (2023)
Permanent URL http://hdl.handle.net/2078.1/267736